500 results on '"Afdhal, N."'
Search Results
2. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension
3. Real‐world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study
4. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States
5. Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection
6. Supplement to: Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
7. Supplement to: Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
8. Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States
9. Welcome to the new, all electronic Journal of Viral Hepatitis
10. Supplement to: Response-guided telaprevir combination treatment for hepatitis C virus infection.
11. Non-invasive assessment of liver fibrosis: O111
12. Watchful waiting: role of disease progression on uncertainty and depressive symptoms in patients with chronic Hepatitis C
13. Sofosbuvir and ribavirin for the treatment chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety
14. Integrated safety analysis of sofosbuvir-based HCV treatment regimens from phase 3 studies
15. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides
16. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices
17. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3
18. Screening: saliva and blood-based screening assays: O112
19. Ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin: FP03–02
20. Potentially curative treatment in patients with hepatocellular cancer—results from the liver cancer research network
21. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C
22. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response
23. Transient elastography for predicting clinical outcomes in patients with chronic liver disease
24. The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis – a pilot study
25. The optimal cut-off for predicting large oesophageal varices using transient elastography is disease specific
26. PGI7 EVALUATION OF LIVER OUTCOMES RELATIVE TO USE OF GLP-1 RECEPTOR AGONISTS (GLP1A) AND/OR SGLT-2 INHIBITORS (SGLT2I) IN REAL-WORLD POPULATIONS DIAGNOSED WITH TYPE II DIABETES (T2DM) AND NASH/NAFLD OR AT RISK OF NASH
27. PGI3 LEAN AND OBESE PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) / NON-ALCOHOLIC FATTY LIVER DISEASE (NALFD); COMPARISONS OF POPULATIONS AND DISEASE PROGRESSION
28. PIN2 REAL-WORLD EFFECTIVENESS OF HEPATITIS C VIRUS (HCV) TREATMENT WITH DIRECT-ACTING ANTIVIRALS (DAA) IN POPULATIONS WITH FATTY LIVER/NON-ALCOHOLIC STEATOHEPATITIS (FL/NASH), DECOMPENSATED CIRRHOSIS (DCC), HEPATOCELLULAR CARCINOMA (HCC), AND/OR POST LIVER TRANSPLANT (PTX)
29. PIN7 REAL-WORLD EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS (DAA) IN YOUNG ADULT (18-25) AND ELDERLY (80+) POPULATIONS WITH HEPATITIS C (HCV)
30. PIN8 HEPATITIS B TREATMENT PATTERNS IN US CLINICAL CARE FOLLOWING TENOFOVIR ALAFENAMIDE (TAF) APPROVAL
31. IL28B polymorphism is associated with intrahepatic ISG expression and peginterferon-α/ribavirin response rate in chronic HCV infection
32. Thrombocytopenia in chronic liver disease – treatment implications and novel approaches
33. Pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection
34. Mucin: Aggregation and colloidal interactions of relevance to some biomedical problems
35. Seventeenth Sir Peter Freyer memorial lecture and surgical symposium: September 23rd & 24th, 1993
36. Irish society of gastroenterology: Proceedings of Winter Meeting held 4th/5th December 1992in Beaumont hospital, Dublin
37. Irish Society of Gastroenterology: Proceedings of meeting held November 1990
38. An unusual cause of abdominal pain in a patient with hepatitis C cirrhosis
39. Irish Society of Gastroenterology: Proceedings of meeting held in Dublin, 7th & 8th June, 1991
40. Controlled trial of antimycobacterial therapy in Crohn's disease: Clofazimine versus placebo
41. Irish society of Gastroenterology: Proceedings of summer meeting, boole auditorium, university college, cork on friday 27th and saturday 28th may, 1988.
42. Irish society of gastroenterology: Proceedings of Spring Meeting, University College, Galway on Friday 9th and Saturday 10th June, 1989.
43. PIN9 CLINICAL PRACTICE EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) FOR TREATMENT OF HEPATITIS B IN THE US
44. PIN79 ACCESS TO HCV CURE UNDER MEDICAID PROGRAMS IN THE UNITED STATES
45. pH-dependent Gelation of Gastric Mucin
46. Squamous metaplasia of extrahepatic biliary system in an AIDS patient with cryptosporidia and cholangitis
47. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network
48. Evaluation of SOMAscan as a discovery platform to identify noninvasive protein biomarkers for diagnosis and monitoring of NASH
49. Utilization and outcomes of elbasvir/grazoprevir in genotype 1B chronic hepatitis C: updated retrospective data analyses from the Trio network
50. Accurate prediction of clinical disease progression in patients with advanced fibrosis due to NASH using a Bayesian machine learning approach
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.